Spero Therapeutics Inc SPRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
-
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
-
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
-
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Trading Information
- Previous Close Price
- $1.17
- Day Range
- $1.13–1.17
- 52-Week Range
- $1.08–3.08
- Bid/Ask
- $1.13 / $1.15
- Shares Outstanding
- 58.23M
- Market Cap
- $65.81M
- Volume/Avg
- 203,271 / 925,255
Key Statistics
- Price/Earnings (Normalized)
- 9.90
- Price/Sales
- 1.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
Valuation
|
Metric
|
SPRO
|
|---|---|
Price/Earnings (Normalized) | 9.90 |
Price/Book Value | 1.54 |
Price/Sales | 1.63 |
Price/Cash Flow | 5.44 |
Price/Earnings
SPRO
Financial Strength
|
Metric
|
SPRO
|
|---|---|
Quick Ratio | 6.03 |
Current Ratio | 6.12 |
Interest Coverage | — |
Quick Ratio
SPRO
Profitability
|
Metric
|
SPRO
|
|---|---|
Return on Assets (Normalized) | 18.52% |
Return on Equity (Normalized) | 25.52% |
Return on Invested Capital (Normalized) | 21.14% |
Return on Assets
SPRO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%J$DrB | LOCK|ggMk | $133B | |||
| Moderna Inc
MRNA
| LOCK|X&$%l! | LOCK|G&J | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#c^?lRY | LOCK|p!wC | $83B | |||
| argenx SE ADR
ARGX
| LOCK|&>&W%m | LOCK|bd | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|lB&kq! | LOCK|JZ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bGyQC#P | LOCK|B!q#R | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?$W>#Qs | LOCK|MLJ!M | $28B | |||
| Incyte Corp
INCY
| LOCK|l@!#wp | LOCK|S^? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<!>ZS$ | LOCK|Rr | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%FtG^L< | LOCK|d& | $14B |
United States